This article was originally published in The Gray Sheet
Atlanta-based firm says it will commence studies in late June to evaluate the surgical adhesive for aortic dissections under an approved conditional investigational device exemption. The final protocol, including the number of patients and centers to be enrolled and the clinical endpoints, still must be hashed out between Cryolife and agency officials. The product gained a CE mark Jan. 6 and began shipping in Europe in mid April
You may also be interested in...
An upturn in M&A activity across the whole healthcare sector is expected in 2021, with the COVID-19 pandemic and the associated development of a vaccine shining a light on the sector, says a recent survey by Jefferies.
Australian patients with phototoxicity due to the rare condition EPP will now have their first treatment option – provided the drug's developer, Clinuvel, secures reimbursement under the Pharmaceutical Benefits Scheme.
Roche has partnered with Regeneron and Atea, but the company continues to leverage its long legacy in infectious diseases to identify good treatment options for the novel coronavirus.